Healthcare News

Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB), greentech industriale specializzata nello sviluppo di soluzioni microbiologiche naturali basate sullo sfruttamento...

Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba (FR0011051598 - ALMIB), een industrieel greentech-bedrijf gespecialiseerd in de ontwikkeling van natuurlijke microbiologische oplossingen op basis...

Chassieu, July 01, 2026 (GLOBE NEWSWIRE) -- Amoéba obtém autorização de colocação no mercado em França para o seu biofungicida AXPERA Chassieu (França), 30 de junho de 2026 – 7h30 - A Amoéba...

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the...

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris PARIS, France, 1er juillet 2026 – 14h35 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou...

SERB Pharmaceuticals has completed the acquisition of development and commercialization rights to Idefirix (imlifidase) in Europe

SOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating...

Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00...

Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares Le montant de l'offre a été augmenté de 600 M$ à 800 M$, à un prix de...

Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025 Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside...